257 related articles for article (PubMed ID: 16964393)
1. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
[TBL] [Abstract][Full Text] [Related]
2. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
3. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
Sakai H
Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
[TBL] [Abstract][Full Text] [Related]
4. [Clinical importance of serum anti-p53 antibodies as tumor markers].
Sakai H; Okamoto E
Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
[TBL] [Abstract][Full Text] [Related]
5. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
6. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring].
Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303
[TBL] [Abstract][Full Text] [Related]
7. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
11. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
12. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
[TBL] [Abstract][Full Text] [Related]
13. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status.
Volkmann M; Müller M; Hofmann WJ; Meyer M; Hagelstein J; Räth U; Kommerell B; Zentgraf H; Galle PR
Hepatology; 1993 Sep; 18(3):559-65. PubMed ID: 7689531
[TBL] [Abstract][Full Text] [Related]
14. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.
Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY
Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857
[TBL] [Abstract][Full Text] [Related]
15. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma.
Maehara Y; Kakeji Y; Watanabe A; Baba H; Kusumoto H; Kohnoe S; Sugimachi K
Cancer; 1999 Jan; 85(2):302-8. PubMed ID: 10023696
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Genazzani AR
Anticancer Res; 1998; 18(5B):3763-5. PubMed ID: 9854491
[TBL] [Abstract][Full Text] [Related]
18. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
19. Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions.
Porrini R; Vercellino V; Rocchetti V; Renò F; Giorda E; Pomato E; Cannas M; Sabbatini M
Minerva Stomatol; 2010 May; 59(5):233-9, 239-43. PubMed ID: 20502428
[TBL] [Abstract][Full Text] [Related]
20. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]